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The metabolic syndrome is basically a maturity-onset disease. Typically, its manifestations
begin to ﬂourish years after the initial dietary or environmental aggression began. Since
most hormonal, metabolic, or defense responses are practically immediate, the procras-
tinated response do not seem justiﬁed. Only in childhood, the damages of the metabolic
syndrome appear withminimal delay. Sex affects the incidence of themetabolic syndrome,
but this ismore an effect of timing than absolute gender differences, females holding better
than males up to menopause, when the differences between sexes tend to disappear.The
metabolic syndrome is related to an immune response, countered by a permanent increase
in glucocorticoids, which keep the immune system at bay but also induce insulin resistance,
alter the lipid metabolism, favor fat deposition, mobilize protein, and decrease androgen
synthesis. Androgens limit the operation of glucocorticoids, which is also partly blocked
by estrogens, since they decrease inﬂammation (which enhances glucocorticoid release).
These facts suggest that the appearance of the metabolic syndrome symptoms depends
on the strength (i.e., levels) of androgens and estrogens. The predominance of glucocorti-
coids and the full manifestation of the syndrome inmen are favored by decreased androgen
activity. Low androgens can be found in infancy, maturity, advanced age, or because of their
inhibition by glucocorticoids (inﬂammation, stress,medical treatment). Estrogens decrease
inﬂammation and reduce the glucocorticoid response. Low estrogen (infancy, menopause)
again allow the predominance of glucocorticoids and the manifestation of the metabolic
syndrome. It is postulated that the equilibrium between sex hormones and glucocorticoids
may be a critical element in the timing of the manifestation of metabolic syndrome-related
pathologies.
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INTRODUCTION
Genetic (Loos and Bouchard, 2003), epigenetic (Gluckman and
Hanson, 2008), environmental (Romao and Roth, 2008), and
mainly dietary (Sclafani and Springer, 1976; Seidell, 1998; Men-
doza et al., 2007) causes of the metabolic syndrome exert their
effects principally through the modulation of the expression of
proteins (enzymes, transporters, regulatory agents). These agents
carry out their functions only within short periods of time because
of their relatively fast turnover, since a short life is one of the basic
premises of any regulatory agent. In the same way, wearing out,
saturation, and exhaustion of metabolic pathways and control sys-
tems could not either extend too much far away in time from the
actual active life of the agents implicated, i.e., the half-lives of
proteins, or the life-span of the cells affected. In short, if the devel-
opment of obesity (or other metabolic syndrome-related disease)
depends on excessive energy or fat intake and the wearing out
of the systems controlling fat deposition (Virtue and Vidal-Puig,
2009), then, it should be expected that the metabolic syndrome-
induced derangements should appear shortly after the initiation
of the inﬂammatory processes and regulatory systems’ alteration.
However, the expected changes usually do not occur shortly after
exposure to triggering agents. Often a number of years elapse
before the symptoms of the metabolic syndrome appear and the
cluster of related diseases fully develops (Gustafsson et al., 2011).
In addition, the metabolic syndrome tends to appear more often
and/or earlier in adult males than in females (Regitz-Zagrosek
et al., 2007; Hong et al., 2009; Gustafsson et al., 2011), the differ-
ences in incidence decreasing sharply after menopause (Janssen
et al., 2008). There are sex-related differences, but the regulatory
mechanisms and metabolic pathways affected are the same. Then,
why are there so marked sex-related differences in the incidence of
the metabolic syndrome? And also, why does this delay in its full
manifestation occurs?
There is also a growing incidence of infantile obesity (Bua
et al., 2007; Patton et al., 2011), i.e., an accelerated presentation of
metabolic syndrome diseases fairly shortly after exposure to envi-
ronmental (i.e., diet, sedentary behavior) obesogenic conditions
(Butte, 2009; Tamayo et al., 2010; Bleich et al., 2011; Guinhouya
www.frontiersin.org February 2012 | Volume 3 | Article 27 | 1
Alemany Steroid hormones and metabolic syndrome development
et al., 2011). Why the delay between triggering factors and disease
manifestation is much shorter in children than in adults?
We cannot directly attribute the differences to genetic factors
(usually shared), neither to the nature of pathogenic mechanisms:
usually lack of exercise (Rey-López et al., 2008; Mitchell et al.,
2009), social tensions and stress (Moschonis et al., 2010; Tamayo
et al., 2010; Gundersen et al., 2011), and mainly, excess dietary
energy and predominance of lipids in the diet (Kohen-Avramoglu
et al., 2003; Zimmermann and Aeberli, 2008). The proinﬂam-
matory mechanisms are shared too (Valle et al., 2005; Kowalska
et al., 2008; Rizvi, 2009; Maury and Brichard, 2010). In addition,
the sex differences are practically inexistent in children (Dubose
et al., 2006), but tend to become manifest already in adolescents
(Duncan et al., 2004), a harbinger of the adult appearance of the
metabolic syndrome.
THE PROTRACTED DEVELOPMENT OF THE METABOLIC
SYNDROME
The mechanisms explaining the metabolic alterations observed
in the diseases of the metabolic syndrome cluster, when known,
seldom refer to the delay in the process of presentation of the syn-
drome. This raises a number of key questions which are critical for
our understanding of the (adult) metabolic syndrome, its roots,
maintenance, development, and eventual treatment.
A. How can some people never develop obesity and others do it
early under similar exposure to diet and environmental factors
(Blundell et al., 2005)? This is apparently incongruous with
our acceptance that genetic stock is not the key factor for most
obesities (Loos and Bouchard, 2003). How can some people
keep ingesting huge amounts of lipids (saturated, cholesterol-
laden, etc.) with no apparent problems whatsoever, and other
people develop obesity even ingesting supposedly very healthy
and monastically scarce diets for life (Ravussin et al., 1988)?
Can we ﬁnd the differences in the genes?
B. We know (or consensually assume) the causes (diet, genetics,
environment) of the metabolic syndrome, and we also know its
results or consequences (obesity, diabetes, hypertension, etc.).
Nevertheless, the effects do not immediately follow the expo-
sure to the triggering agents. A fairly long period of time is
usually needed for these factors to ﬁnally manifest their delete-
rious effects (Parker et al., 2003; Ramsay et al., 2008;Gustafsson
et al., 2011). Then,how can ourmetabolic systems (whichwork
reacting immediately to substrate or regulator concentrations,
hormonal signals, gene expression, etc.) wait years to develop
metabolic syndrome-related diseases. In addition, the effects
of these uncovered illnesses cannot be easily reversed by exer-
cise (Thomas et al., 2010), low energy diets, with even lower
lipid (Straznicky et al., 2010) or the ultimate surgical removal
of excess fat (Varela et al., 2008)? What is the basis for this
double-sided inertia?
C. What is the limit line that links the original dietary aggres-
sion and the metabolic syndrome constellation of diseases?
Why are there differences in the pattern of manifestation
of metabolic syndrome diseases in different people? Is there
a sequence of events or a shotgun massive development of
parallel pathologies?
There is an enormous body of information on these issues, but
there is also a huge void in place of serious integrative analysis
of a disease that has been intuitively considered a unique pathog-
nomic entity (Bruce and Byrne, 2009) even before serious studies
on its pathogenicity began. The center of study is progressively
descending into detail to the molecular level (Nicolson, 2007;
Maury and Brichard, 2010), usually forfeiting the integration of
these data within the context of a living being, and adding com-
plexity and background noise to any contextual analysis of the
situation (Miranda et al., 2005).
METABOLIC AND REGULATIVE CHANGES ELICITED BY THE
METABOLIC SYNDROME
The mechanisms so far presented to explain the pathogenicity of
the metabolic syndrome should induce signiﬁcant changes in a
very short period of time, since:
1. The rheologic alterations caused by red blood cells undeforma-
bility, a more than probable contributor to hypertension (Cicco
and Pirrelli, 1999), can appear in a few months, since the mean
half-life of an erythrocyte is in the range of 120 days. If the
postulated modiﬁcation of their membrane ﬂuidity is set dur-
ing the lifetime of the cell, then it should be apparent in a few
months. Continuity would depend on new cells substituting
the destroyed red cells and on them becoming again altered
by glycosylation, oxidation, nitration, etc., losing membrane
ﬂexibility in the process. However, the conditions after a few
months should remain unchanged for years to come,maintain-
ing perhaps a hypertensive situation,butwith no possible direct
incidence whatsoever on further aggravating the situation.
2. The excess glucose and excess lipid ingested and not processed
are ﬁnally accumulated into fat depots after all other outlets
have been topped up (increased energy expenditure includ-
ing thermogenesis, higher protein accumulation and turnover,
higher levels of glycogen, etc.). Most of this lipid is found
in white adipose tissue (WAT), and part in liver and muscle.
However, WAT is the main site for storage of excess fat. Any
maintained excess of energy would end being part of accumu-
lated fat inWAT. However, this is not – again – the case. Usually,
WAT does not grow indeﬁnitely to monstrous proportions (Jo
et al., 2009). In fact, many obese and overweight individu-
als maintain their (excessive) weight fairly well thanks to an
operative (albeit misadjusted) ponderostat setting (Bradley,
1978). There is something that prevents WAT from growing
indeﬁnitely, a defense system based on the coordinated opera-
tion of immune system cells’ inﬁltration, which help produce
cytokines that reorganize the body energy handling proto-
cols (Cancello and Clément, 2006; Pang et al., 2008; Alemany,
2011b), but also prevent that WAT receives excess energy. In
the end WAT informs the brain (probably through pondero-
stat signals) that the optimal level of fat stores is overcome
(Bradley, 1978; van Itallie, 1990). In addition, WAT glycolyzes
excess glucose (normally under hypoxic conditions) and pro-
duces lactate, resulting in local acidosis (Hagström et al., 1990;
Muñoz et al., 2010); there is a marked vasoconstriction (largely
cytokine or catecholamine-driven) than compounds the effects
of acidosis to induce a marked hypoxia that exacerbates the
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secretion of cytokines and other signals (Wang et al., 2007,
2008), as well as increasing the glycolytic loop. As a conse-
quence, WAT is defended against excess lipid accumulation.
But all this sequence occurs in a few weeks, perhaps months,
but not years! After WAT has grown to its limit and is fully
invaded by cells of the immune system, its function as lipid
storage depot and glycolytic outlet for excess plasma glucose
remain unchanged, and could not be further increased (but can
decrease) despite the maintenance of high levels of energy sub-
strates. Thus, the pathogenic conditions observed in the WAT
of a rat subjected to a high-lipid fattening diet should be the
same in a few weeks than after a few months; nevertheless, the
weight increase soon tappers off, often irrespective of dietary
or surgical restrictive treatments (Sclafani and Springer, 1976;
Greenwood et al., 1982).
3. The accumulation of fat in the liver due to deranged lipopro-
tein turnover, altered cholesterolmetabolism, excess energy and
overall inﬂammation (Wouters et al., 2008; Eguchi et al., 2011;
Subramanian et al., 2011), occurs in parallel to themassive stor-
age of fat in WAT, and has similarly insurmountable timelines
blocking the accumulation of fat beyond the already surpassed
limits of functionality. Possible deterioration of hepatocyte
function encounters –again– the problem of cell cycle duration
and cell component turnover. Most body cells are substituted
(at different speeds, directly related to their activity and procliv-
ity to damage) in relatively short periods, and within these cells,
cell organelles, structures and molecules (largely proteins) are
recycled at speeds ranging from minutes to months (but, again,
not years or decades; Yuile et al., 1959; Millward et al., 1975). In
consequence, damaged tissues are renewed, and maybe dam-
aged again, but the level of damage could not be incremental
(within certain limits) for so much dilated periods, especially
when more often than not, exposure to triggering factors (such
as diet) tends to decrease with time.
4. Changes in cell or tissue function may be the consequence of
genetic, epigenetic,or developmental changes. It seems improb-
able that genetic design may be responsible for delayed mod-
iﬁcation of organ function out of line with the vital function
plans. The epigenetic modiﬁcations, however, may play a more
plausible role, in association with developmental changes [or,
in our case, developmental regression to conditions found only
during lactation (Alemany, 2011a)]. There is, simply, no infor-
mation available on these issues. However, it is improbable that
the changes would be established not to improve –or at least
maintain– the basal original metabolic and regulatory condi-
tions, but to deeply alter these in a way that plays havoc with
energy homeostasis and severely endangers survival. This is not
the way biological change works, and in fact tends to revert the
direction (adaptability) of most inheritable epigenetic changes
(Kaati et al., 2007; Lamm and Jablonka, 2008; Giraudo et al.,
2010).
5. There may be an exhaustion of regulatory or control systems
due to abusive extended exploitation of their capabilities at the
limit of their possibilities, i.e., because of an excessive over-
load of nutrients. This theory has been used to explain the loss
of control (and number) of pancreatic beta cells after massive
secretion of insulin for years (Prentki and Nolan, 2006). This
may be a possibility, but in most metabolic syndrome cases,
there is a marked overproduction of insulin, which results
in hyperinsulinemia, ineffective because of insulin resistance
(Prager et al., 1987; Shanik et al., 2008). In some instances, beta
cells die, and then type 1 diabetes develops as ﬁnal stage of type
2 diabetes (Donath et al., 2005). The possibility of exhaustion
or loss of function can be applied only to very special cells,
such as neurons (and, perhaps, pancreatic beta cells; Prentki
and Nolan, 2006; Ayarapeytanz et al., 2007), since most cells
are subjected to turnover, and the body usually retains efﬁ-
cient mechanisms to compensate for deﬁcits or excesses [e.g.,
muscle mass development/loss depending on use (van der Hei-
jden et al., 2010), brown adipose tissue mass depending on
cold exposure (Bukowiecki et al., 1982), or WAT masses, that
are enlarged or shrunk depending on the availability of energy
(Morkeberg et al., 1992)].
SCHEDULES FOR DEVELOPMENT OF THE METABOLIC
SYNDROME IN ADULTS
The dilated timing of development of most cases of the metabolic
syndrome in adults ﬁts fairly well with the patterns of change,
over the long-term, of androgens and estrogens (as well as of
the postulated estrone-derived ponderostat signal), and are far
away from the rapid change associated with peptide hormones,
catecholamines, and most metabolic regulative signals. Steroid
hormones are also synthesized in the brain, and freely cross the
blood–brain barrier (Pardridge and Mietus, 1979; Baulieu and
Robel, 1990), their circulating half-lives are longer than those of
peptide or protein hormones and have no difﬁculties in cross-
ing through or interacting with the cell membranes (Rao, 1981;
Oren et al., 2004); they may even have membrane-bound recep-
tors (Nemere andFarach-Carson,1998; Jain et al., 2005) or binding
proteins (Fortunati et al., 1996).
A plausible way to explain the delay in the appearance in full
regalia of the metabolic syndrome in adults is to consider the brain
responsible for the timing and progressive alterations that charac-
terize its appearance. This theory is based mainly in the possibility
to change (or misadjust) the ponderostat setting by a number
of (largely unknown) conditions, such as a psychiatric disorder
(Tuthill et al., 2006), iatrogenic effects of some drugs [Schwartz
et al., 2004; Virk et al., 2004; or environmental poisons (Irigaray
et al., 2006)], hypercortisolism (Peeke and Chrousos, 1995; Björn-
torp and Rosmond, 2000), long time exposure to fattening food
(nil for some people, very fast for others; Seidell, 1998; Blundell
et al., 2005), coincidence of a combination of alleles from a long
list of genes (Borecki et al., 1998; Swarbrick and Vaisse, 2003),
in utero conditioning (Beall et al., 2004; DeSai et al., 2005), epi-
genetic inheritance (Whitaker et al., 2010), triggering of thrifty
genes (Romao and Roth, 2008), etc. The ponderostat setting also
changes along our lives, so that mature men tend to present wider
girths than younger adults (Yoshinaga et al., 2002;Alley andChang,
2010). These long-termcycles are essentially governedby the brain,
which ultimately favors the secretion of androgens and estrogens
(but also the stress-immunity hormones, glucocorticoids; Mauras
et al., 1996; Demerath et al., 1999; Matchock et al., 2007).
The list of factors potentially modifying body fat set-point is
longer: estrone (Ferrer-Lorente et al., 2005; and the ponderostat
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signal derived from estrone; Vilà et al., 2011) dehydroepiandros-
terone (Tchernof and Labrie, 2004), progesterone, aldosterone. In
addition, the possibilities of regulation include retinoids (Kriegs-
feld and Silver, 2004), hydroxycalciferols (Wortsman et al., 2000),
hormone-transporting globulins (Barat et al., 2005; Li et al., 2010),
and especially, hormone receptors (Mauvais-Jarvis, 2011).
THE ROLES OF STEROID HORMONES
Androgens are closely related to insulin (or IGF-1; Shefﬁeld-
Moore, 2000) and growth hormone (Mauras, 2006) as anabolic
protein-deposing agents (Griggs et al., 1989). Estrogens are antiin-
ﬂammatory (Schaefer et al., 2005; Straub, 2007), antioxidant pro-
tective agents (Prokai et al., 2005; Reyes et al., 2006). And glucocor-
ticoids are defense agents (and thus faster-acting; Orchinik et al.,
1994) which prevent and correct damages (Hafezi-Moghadam
et al., 2002), and control the immune system (Franchimont, 2004;
Tait et al., 2008).
The roles for androgens and estrogens go much beyond their
function as sexual and reproductive hormones. In the metabolic
syndrome, androgens’ levels (Gooren, 2006; Gould et al., 2007;
and to a lesser extent estrogens) decrease considerably (and cor-
ticosteroids increase; Duclos et al., 2005) in parallel to advancing
age (Blouin et al., 2005). However, androgens decrease earlier and
more markedly. This seems to be the main deviation from the pre-
established normal (i.e., non-metabolic syndrome) pattern. The
dependence of the pathologic manifestations of the metabolic
syndrome on the secretion, availability, and function of steroid
hormones can be speculatively established by:
A. Lower levels of dehydroepiandrosterone (Howard, 2007) give
rise to lower levels of adrenal gland-derived androgens (Haring
et al., 2009;Akishita et al., 2010); since the levels of estrogens are
more or less maintained (at least until menopause in women,
and even in old age in men), the drainage of androstenedione
and testosterone must be even higher, causing hypoandro-
genism. Glucocorticoid-induced leptin resistance (Ur et al.,
1996; Zakrzewska et al., 1997) may diminish leptin effects
on gonadotropin-releasing hormones (Barb et al., 2004), thus
diminishing the secretion of sex hormones from testicle and
ovary. In the testicle, this may result in decreased production
of testosterone and, consequently, hypotestosteronemia; but in
the ovary, extraovaric production of estrogen (WAT, breast;
Klein et al., 1996) may partially compensate the decrease of
ovaric synthesis, but at the expense of dwindling androgen lev-
els. In addition, dehydroepiandrosterone plays a critical role
in the intestinal partition of protein N (Wu, 1996) and is a
powerful antiglucocorticoid (Kalimi et al., 1994). Low DHEA
may alter the synthesis of intestinal carbamoyl-P (and thus the
overall synthesis of urea; Marrero et al., 1991). DHEA levels
are closely relatedwith survival in adults (Barrett-Connor et al.,
1986; Berr et al., 1996), a factor that givesweight to this essential
purported role. In humans, dehydroepiandrosterone-sulfate is
the main corticosteroid secreted to the bloodstream, and is
thus the principal adrenal cortex-secreted hormone (Ebeling
and Koivisto, 1994).
B. Hypoandrogenism decreases protein synthesis and turnover
(Urban et al., 1995; Shefﬁeld-Moore, 2000), thus lowering
energy and amino acid needs. Low testosterone also affects
insulin effectiveness, favoring insulin resistance in WAT (Cor-
bould, 2007), but mainly decreasing overall insulin resistance
associated to the metabolic syndrome (Kapoor et al., 2006;
Traish et al., 2009). Hypoandrogenism results in smaller mus-
cle mass, and consequently, in lower muscle energy needs,
indirectly aggravating the problems of insulin resistance. In
women, insulin or IGF-1 directly favors the synthesis of andro-
gens in ovaries and adrenals (Nestler, 1997; Guercio et al.,
2003), whilst in men, the main inﬂuence is exerted through
stimulation of FSH production (Livingstone and Collison,
2002). Insulin resistance is associated to lower androgen levels
(Grossmann et al., 2008; Yeap et al., 2009) in men, because of
lower testicular production (Pitteloud et al., 2005), but not
in post-menopausal women or those with polycystic ovary
syndrome (Coviello et al., 2006; Al-Ozairi et al., 2008). The
differences in androgen availability and handling may help
explain some of the sex-related differences in the onset and
development of the metabolic syndrome. In any case, the ques-
tion is compounded by the inhibition of androgen synthesis
induced by glucocorticoids (Dong et al., 2004), the increase
in overall aromatase activity consequence of increased WAT
mass, and the critical role of this tissue in the synthesis of
estrogen (Cleland et al., 1985). Thus, obesity is directly related
to decreasing androgens’ levels, aggravating the pathological
situation by negative feedback.
C. Relative decrease in the availability of estrogen because of lower
availability of SHBG (Heald et al., 2005; Weinberg et al., 2006),
but also, in part, because of lower levels of DHEA precursor
(Janson et al., 1982;Depergola et al., 1991; Turkmen et al., 2004;
Howard, 2007). Low estrogen levels may reduce their protec-
tive effects on endothelial cells (Dai et al., 2004; Ling et al.,
2006), nervous system cells (Pozzi et al., 2006; Suzuki et al.,
2006), trauma-related inﬂammation (Yokoyama et al., 2003),
and antiapoptotic effects (Hosoda et al., 2001; Liu et al., 2011).
D. High glucocorticoid activity negatively affects proteinmass and
its maintenance (Tomas et al., 1979; Löfberg et al., 2002), favor-
ing amino acid oxidation (Block et al., 1987; England and Price,
1995). Glucocorticoids induce insulin resistance (Asensio et al.,
2004; Ruzzin et al., 2005) and leptin resistance (Ur et al., 1996).
They tend to counteract catecholamine effects (Mannelli et al.,
1994; Lambert et al., 2010), allowing the deposition of fat in
most cell types (Asensio et al., 2004).
E. Deranged maintenance of ponderostat settings caused by –or
parallel to– altered secretion/detection of ponderostat sig-
nals, including sensitivity to peptides [leptin (Eikelis et al.,
2007), adiponectin (Tomita et al., 2008)] and the postulated
estrone-derived ponderostat signal (Vilà et al., 2011).
Globally, in the metabolic syndrome there is a decrease in all
functions related to the androgen–estrogen system, with a par-
allel increase (by stress, counteraction, or previously established
genetic design) of glucocorticoids. This is a rather sketchy expla-
nation, which requires more data, since there is a considerable
lack of information on the long-term changes of these hormones’
metabolism, the polycystic ovary syndrome being a signiﬁcant
exception (Kauffman et al., 2008; Guastella et al., 2010). The role
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of glucocorticoids in the genesis and maintenance of obesity has
been widely studied (Livingstone et al., 2000; Achard et al., 2006),
but seldom in relation to other types of steroid hormones.
EFFECTS OF ALTERATIONS IN STEROID HORMONE
EQUILIBRIUM BALANCE
A very important environmental factor, that may play a signiﬁcant
role in the unbalancing of the steroid hormone equilibrium, is
the massive use of steroids as drugs for the treatment of a large,
diverse, and growing number of diseases, corticosteroids being a
case in point (van der Laan and Meijer, 2008). Synthetic gluco-
corticoids are widely (albeit not always sagely) used in Medicine
(Borchers et al., 2003). They elicit marked effects through classical
glucocorticoid receptors (Rousseau et al., 1972), but they are not
subjected to the normal (physiological) systems of control; i.e.,
dexamethasone may bind the glucocorticoid receptors and elicit a
blockage response of corticotropin secretion (Pasquali et al., 2002),
but it does not bind the corticosteroid-binding globulin (West-
phal, 1969; Perogamvros et al., 2011), a key element in the control
of glucocorticoids (Grasa et al., 2001; Perogamvros et al., 2011).
There is also a growing challenge in environmental antian-
drogens (Hotchkiss et al., 2008), and, especially, estrogenic com-
pounds (Shappell, 2006; Foster, 2008), found almost anywhere
as contaminants, that reinforce part of the actions of estrogens
(but not along the whole spectrum of their functions; Knight and
Eden, 1996; Ørgaard and Jensen, 2008), and are neither subject to
their physiological mechanisms of control (Mueller et al., 2004;
Wang et al., 2010). These effects are more marked in some tis-
sues (gonads, mammary glands; Cassidy, 1999; Dang, 2009), and
in the induction of estrogen-dependent cancer (Ososki and Ken-
nelly, 2003), but we do not know much about their effects on
brain and on endothelial inﬂammation processes. Environmental
estrogens may diminish the secretion of gonadotropins (McGar-
vey et al., 2001), depriving the body of necessary estrogens acting
on a wide spectrum of places, and substituting their ﬁnely tuned
function by unspeciﬁc sexual hormone-like-related tissue stimu-
lation. Food is an important source of unnecessary or unwanted
estrogen (Remesar et al., 1999; Malekinejad et al., 2006; often with
a wide spectrum of functions), promoting out of tune growth and
fat deposition, as is the case of animal fats (Holmes et al., 2000),
isoﬂavones (Suetsugi et al., 2003; Choi et al., 2008), and especially,
dairy products (Malekinejad et al., 2006). Estrogen is present in
the milk as a growth factor that helps the suckling to better use the
milk nutrients (Remesar et al., 1999), but milk was not designed
to feed adults. . . which thus receive repeated and potentially dam-
aging doses of dietary estrogen (Qin et al., 2004) and other growth
–including diabetogenic– factors (Martin et al., 1991; Wasmuth
and Kolb, 2000).
A peculiarity of steroid hormones is their considerable abil-
ity to interconvert to different molecular species, forming families
of compounds that show different global activity, but also marked
differences in metabolic roles, such is the case of estrone and estra-
diol (Miller, 1969; Myking et al., 1986; Kirilovas et al., 2007). The
simpliﬁed panorama described above must be completed with
the inﬂuence of agents different from the typical estradiol for
estrogen, testosterone for androgen and cortisol (corticosterone in
rats) for glucocorticoids. Receptor dimerization and complexity
[Sonoda et al., 2008; including their presence in the cell
surface (Kim et al., 2008; Levin, 2009) and/or nucleus/cytoplasm
(Welshons et al., 1984; Sebastian et al., 2004)], is compounded by
the existence of converting enzymes, typically aromatase (Simp-
son, 2000; Miller, 2006), 17βOH- (Labrie et al., 1997; Adamski and
Jakob, 2001) and 11βOH-steroid dehydrogenases (Agarwal, 2003;
Isomura et al., 2006).Other hormones, such as progesterone,play a
particular role under speciﬁc conditions (i.e., pregnancy; Spencer
and Bazer, 2002; Gellersen et al., 2009) or act as supplemental sig-
nals for the three classical lines described, largely glucocorticoid
(and antiglucocorticoid) effects (Pedersen et al., 2003; Zhang et al.,
2007).
CHILDHOOD MANIFESTATION OF THE METABOLIC
SYNDROME
The existence, and growing incidence (Yoshinaga et al., 2004;
Reilly, 2005), of infantile and juvenile obesity, compounded by
other manifestations of the metabolic syndrome (Goran and
Gower, 1998; Rosenbloom, 2003; Tauman andGozal, 2006) appar-
ently seems to be contradictory with the delayed appearance of
the metabolic syndrome in full maturity. In some cases, obesity
appears fairly early, even during infancy (Yoshinaga et al., 2004).
This same phenomenon can be observed in rats, weaned on high-
lipid cafeteria diet (Maxwell et al., 1988), which grow faster for
a time and become obese at an early age (Bayol et al., 2005).
The causes of childhood obesity are considered a combination of
genetic (Wardle et al., 2008) and environmental factors: sedentary
behavior (Tremblay and Willms, 2003), but mainly overnutrition,
with abundance of lipid (Ailhaud and Guesnet, 1997; Macé et al.,
2006). The role of diet, however, is far from being fully proven
(Newby,2007). Thepresence of growth factors in the diet, i.e., from
milk (Remesar et al., 1999) or meats (Meyer, 2001) is a signiﬁcant
factor contributing to the early manifestation of obesity. Child-
hood obesity is parallel to serious disturbances of the endocrine
system, including advanced menarche in girls (Freedman et al.,
2003), hypogonadism or delayed puberty (Kaplowitz, 1998) and
gynecomastia (Ersöz et al., 2002) in boys, and a generalized ten-
dency to altered cortisol function (i.e., depression; Goodman and
Whitaker, 2002; Dockray et al., 2009).
The rapid development of the metabolic syndrome in chil-
dren exposed to obesogenic diets and other metabolic syndrome-
inducing factors in fact is not toomuchdifferent from the situation
in mature adults: in both cases, androgens and estrogens have not
yet achieved their adult levels of functionality (or are in frank
decline in mature subjects). Both situations have in common
the low levels/availability of these steroid hormones. In fact, in
children there is a higher response to hormones inducing the accu-
mulation of body fat, as is the case of estrone (Tang et al., 2001).
As expected, the setting on of childhood obesity also alters the
normal sexual development into adulthood (Esposito et al., 2008;
Goldbeck-Wood, 2010). This condition affects boys more deeply
than girls, especially when environmental or iatrogenic factors
delay their gonadal development, affect their fertility andmaintain
low testosterone levels throughout (Rozati et al., 2002; Sikka and
Wang, 2008).
The differences in the timing of metabolic syndromemanifesta-
tion in children and adults agree with low androgen and estrogen
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FIGURE 1 | Interactions between glucocorticoids and sexual hormones in
the regulation of the manifestation of the metabolic syndrome-related
pathologies. Excess substrate availability, genetic predisposition, and other
factors induce inﬂammation, which triggers the manifestation of the
metabolic syndrome. This is favored by low androgen/glucocorticoid activity
ratio (A/G ratio) and low estrogen/glucocorticoid activity ratio (E/G ratio).When
sexual maturity is attained, secretion of both androgens and estrogens raise
the ratios, both because of direct effects on glucocorticoid synthesis and
decreased inﬂammation (estrogen). Inﬂammation and activation of the EPA
axis tends to raise glucocorticoid activity (which negatively interacts with
androgen and estrogen). Low levels of sexual hormones (andropause,
menopause) decrease their capacity to limit the effects of glucocorticoids,
decreasing both A/G and E/G ratios, and allowing the full manifestation of the
metabolic syndrome pathologies. Blue lines: variable effects; green lines:
increasing or enhancing effects; red lines: decreasing or inhibiting effects;
black lines: direct relationships, consequences.
and high glucocorticoid levels in both sections of the life cycle.
However, coincidence is not proof enough, and more studies on
the interactive inﬂuence of sexual hormones in the development
of the metabolic syndrome (or its arrest) are needed to fully sus-
tain the hypothesis presented here. In the case of glucocorticoids,
their direct implication in the development of the metabolic syn-
drome both in childhood and in maturity has been already proven
(Björntorp andRosmond,2000;Wolf, 2002; Spencer andTilbrook,
2011).
OPEN QUESTIONS
The hypothesis presented here does not cover all cases of mani-
festation or control of the metabolic syndrome, since there are a
number of factors which may deeply change or modulate the pre-
sentation of themetabolic syndrome.Genetic factorsmay not only
modulate the proclivity to favor the appearance of the metabolic
syndrome (Goulart et al., 2009; Sookoian and Pirola, 2011), but
may trigger responses inducing disease, such as obesity, through
massive alteration of the mechanisms of control, as is the case of
some genetic-based obesities such as the Prader–Willi syndrome
(Cassidy, 1997). In animal models, such as the Zucker obese rats,
containing the Leprfa/fa mutation (Phillips et al., 1996), we know
the altered mechanism, the lack of responsiveness to leptin. Evi-
dently, these cases could not be correlated with the hypothesis
postulated here, in spite of altered glucocorticoid (Pesonen et al.,
1992) and infertility observed in Zucker obese rats. In humans
with the Prader–Willi syndrome there are alterations (with wide
variations) in sexual maturation (Eiholzer et al., 2006), and hypo-
thalamic steroid hormone regulation (Brandau et al., 2008). In
both cases, despite their large differences in genetic cause and
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triggering agents, steroid hormones’ changes are not at the root
of the problem, but nevertheless their function is deeply altered.
The ponderostat mechanism of control of body weight
(Bradley, 1978) has been postulated as a homoeostatic system in
which the brain regulated energy expenditure and energy intake in
parallel to maintain the desired mass of body fat reserves (Bradley,
1978; Cabanac, 2001). This mechanism is maintained through sig-
nals from adipose tissue informing the brain of the actual fat mass.
Leptin has been postulated as a possible ponderostat signal (Zhang
et al., 1994); it is generally accepted that leptin participates in the
control of energy balance (Gautron and Elmquist, 2011), but not
in this role. Oleoyl-estrone has been also postulated as a pondero-
stat signal (Adán et al., 1999), and its structure and function is
closely related to estrogen (Sanchis et al., 1996). Glucocorticoids
inhibit its lipostatic effects (Grasa et al., 2007), and oleoyl-estrone
modulates increases glucocorticoid synthesis (Romero et al., 2010)
and decreases the synthesis of testosterone (Romero et al., 2009).
However, recent studies have shown that oleoyl-estrone is not the
active agent producing changes in ponderostat setting and meta-
bolic changes, but a derivative of this compound, which structure
has not yet been discovered but which is nonetheless related to
estrogens too (Vilà et al., 2011).
The question of different intensities of manifestation of meta-
bolic syndrome diseases (or their absence) in different individuals
subjected to the same stimuli remains open. Genetic adaptive
factors may play an important role, but so far they are not known,
and neither the possible consequences this resistance plays on (or
is played by) steroid hormones.
CONCLUSION
Steroid hormones are the only known medium- to long-term
signals capable of eliciting procrastinated, often imperceptible,
changes along time that shape our vital cycle. They are also closely
controlled by the brain along pre-established patterns of change,
and probably are also implied in themagniﬁcation of the problems
caused by the metabolic syndrome. These effects in fact largely
reﬂect the lifetime consequences of their own altered equilibrium.
The normal decrease in androgen and estrogen levels along
with advancing age prevent these hormones to overcome the
growing insult of environmental factorswhich elicit a immune sys-
tem defense reaction countered by an increase in glucocorticoids
which prevail over androgens (but also estrogens) to fully allow
the metabolic syndrome and related pathologies to fully manifest.
In consequence, I postulate that the timing of appearance of the
metabolic syndrome-related pathologies is closely linked to paral-
lel decreases in androgens and estrogens, and thus the syndrome
fully ﬂourishedmainly under conditions of low sex hormone levels
(infancy, advancing age in men, menopause in women; Figure 1).
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